What is the recommended testing approach for suspected Lyme disease?

Recommended Testing Approach for Lyme Disease

For patients with typical erythema migrans in an endemic area, diagnose clinically without laboratory testing; for suspected disseminated Lyme disease (neurologic, cardiac, or arthritic manifestations), use two-tiered serologic testing with ELISA followed by immunoblot confirmation. 1

Clinical Diagnosis Without Testing

Erythema migrans should be diagnosed clinically, not serologically. 1 This is a strong recommendation because:

• Laboratory testing has poor sensitivity in early disease (often negative in the first 2-3 weeks)
• The characteristic expanding erythematous rash centered on a tick bite site is sufficiently diagnostic
• Testing delays treatment and adds unnecessary cost

Do not order laboratory tests for typical erythema migrans. The clinical presentation alone is adequate when the patient has:

• Potential tick exposure in an endemic area
• Painless, centrifugally expanding erythema (≥5 cm diameter)
• Rash appearing 3-30 days after tick bite 2

When to Use Serologic Testing

Order antibody testing for suspected disseminated Lyme disease, specifically when patients present with 1:

Neurologic manifestations requiring testing:

• Meningitis
• Painful radiculoneuritis
• Mononeuropathy multiplex
• Acute cranial neuropathies (especially CN VII, VIII, less commonly III, V, VI)
• Spinal cord inflammation with associated radiculitis

Do NOT test for:

• Typical amyotrophic lateral sclerosis
• Relapsing-remitting multiple sclerosis
• Parkinson's disease
• Dementia or cognitive decline
• New-onset seizures
• Developmental, behavioral, or psychiatric disorders in children
• Isolated brain MRI white matter abnormalities without other clinical support 1

Two-Tiered Testing Protocol

The standard approach uses ELISA first, followed by immunoblot confirmation 1, 3, 4:

1. First tier: Enzyme immunoassay (ELISA) for IgM and IgG antibodies
2. Second tier: Western immunoblot performed ONLY if ELISA is positive or equivocal

Critical timing considerations:

• If symptoms <6 weeks and initial serology negative: Repeat testing after 3 weeks 3
• Only IgG antibodies confirm diagnosis in late disease 3
• Isolated IgM positivity beyond 6 weeks typically represents false positive 3

Common pitfall to avoid:

Do not interpret positive IgG as active infection in isolation—IgG may persist for years after successful treatment. Always correlate with clinical presentation and exposure history 3.

Atypical Presentations

For skin lesions suggestive but atypical for erythema migrans: Use antibody testing on acute-phase serum, with convalescent-phase sample 2-3 weeks later if initial result is negative 1. This is preferred over PCR or culture of blood/skin samples.

Lyme Neuroborreliosis Testing

For suspected neuroborreliosis, use serum antibody testing rather than CSF PCR or culture 1.

Intrathecal antibody synthesis is critical for confirming Lyme neuroborreliosis, achieving >99% sensitivity after 6-8 weeks 3. However, isolated antibody index elevation without CSF pleocytosis suggests an alternative diagnosis.

Key distinction:

PCR may be useful from synovial fluid in Lyme arthritis or from skin lesions, but is rarely informative for CSF 3.

Testing Algorithm Summary

Suspected Lyme Disease
    ↓
Endemic area + tick exposure?
    ↓
├─ Typical erythema migrans → Clinical diagnosis, NO TESTING
├─ Atypical rash → Acute serology (+ convalescent if negative)
└─ Disseminated disease (neuro/cardiac/joint) → Two-tiered serology
       ↓
    ELISA
       ↓
    ├─ Negative → Consider repeat in 3 weeks if <6 weeks symptoms
    ├─ Positive/Equivocal → Immunoblot confirmation
    └─ If neuroborreliosis suspected → Add CSF analysis for intrathecal antibody synthesis